1. P203 Development Of An Optimal F/hn Pseudotyped Siv Vector For Cf Gene Therapy. (10th November 2014) Authors: Hyde, SC; Alton, Ewfw; Boyd, AC; Connolly, MM; Chan, M; Davies, JC; Davies, LA; Gea-Sorli, S; Griesenbach, U; Hasegawa, M; Innes, JA; Inoue, M; McLachlan, G; Meng, C; Pringle, IA; Sumner-Jones, SG; Tsugumine, SG; Gill, DR Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A165 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P204 Immune Responses To Single And Repeated Administration Of Pgm169/gl67a: The Uk Cf Gene Therapy Consortium Clinical Trials. (10th November 2014) Authors: Griesenbach, U; Boyd, AC; Calcedo, R; Cheng, S; Cunningham, S; Davies, JC; Dewar, M; Gill, DR; Doherty, A; Higgins, T; Hyde, SC; Manvell, M; Meng, C; Innes, JA; Limberis, MP; Punch, E; Scheule, R; Soussi, N; Soussi, S; Wilson, JM Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P209 Standardisation Of Lung Clearance Index In A Multicentre Clinical Trial. (10th November 2014) Authors: Armstrong, DK; Bayfield, KJ; Alton, EWFW; Boyd, AC; Cunningham, S; Elgmati, HI; Gill, DR; Griesenbach, U; Higgins, TE; Hyde, SC; Innes, JA; Saunders, CJ; Spearing, EJ; Davies, JC Journal: Thorax Issue: Volume 69(2014)Supplement 2 Page Start: A168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P95 Assessment of F/HN-pseudotyped Lentivirus as a Clinically Relevant Vector For Lung Gene Therapy. (19th November 2012) Authors: Griesenbach, U; Inoue, M; Meng, C; Farley, R; Chan, M; Newman, NK; Brum, A; You, J; Kerton, A; Shoemark, A; Boyd, AC; Davies, JC; Higgins, TE; Gill, DR; Hyde, SC; Innes, JA; Porteous, DJ; Hasegawa, M; Alton, EWFW Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P96 Repeat Administration of GL67A/pGM169 is Feasible, Safe, and Produces Endogenous Levels of CFTR Expression After 12 Doses. (19th November 2012) Authors: Alton, EWFW; Boyd, AC; Cheng, SH; Davies, J; Davies, LA; Dayan, A; Gill, DR; Griesenbach, U; Higgins, T; Hyde, SC; Innes, A; McLachlan, G; Porteous, D; Pringle, IA; Scheule, RK; Sumner-Jones, SG Journal: Thorax Issue: Volume 67(2012)Supplement 2 Page Start: A105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. S56 Moving lentiviral-based gene therapy into a first-in-man CF trial. (12th November 2015) Authors: Griesenbach, U; Alton, EWFW; Beekman, JM; Boyd, AC; Chan, M; Davies, JC; Davies, LA; Davidson, HE; Dekkers, JF; Gea-Sorli, S; Gill, DR; Hasegawa, M; Higgins, T; Hyndman, L; McLachlan, G; Inoue, M; Hyde, SC; Moran, C; Meng, C; Paul-Smith, MC Journal: Thorax Issue: Volume 70(2015)Supplement 3 Page Start: A34 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗